Published in Thorax on July 14, 2006
A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis (2008) 2.77
Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis (2009) 1.78
Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health (2010) 1.62
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis (2011) 1.20
Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One (2011) 1.19
The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Philos Trans R Soc Lond B Biol Sci (2014) 1.06
Timing and uptake of ART during treatment for active tuberculosis in HIV co-infected adults in Malawi. Public Health Action (2011) 1.02
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med (2013) 1.01
Knowledge of tuberculosis-treatment prescription of health workers: a systematic review. Eur Respir J (2011) 0.98
Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One (2011) 0.97
A hospital-based tuberculosis focal point to improve tuberculosis care provision in a very high burden setting. Public Health Action (2013) 0.90
Antitubercular therapy in patients with cirrhosis: challenges and options. World J Gastroenterol (2014) 0.86
Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial. PLoS One (2015) 0.85
The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. BMC Infect Dis (2014) 0.82
Alcoholism and other socio-demographic risk factors for adverse TB-drug reactions and unsuccessful tuberculosis treatment - data from ten years' observation at the Regional Centre of Pulmonology, Bydgoszcz, Poland. Med Sci Monit (2014) 0.80
Risk factors associated with adverse reactions to antituberculosis drugs. J Bras Pneumol (2015) 0.79
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection (2013) 0.78
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. Br J Clin Pharmacol (2016) 0.77
Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. PLoS One (2016) 0.76
Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain Behav (2015) 0.76
Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors. HIV Med (2012) 0.76
Biomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase. Adv Pharmacol Sci (2012) 0.76
Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy. J Clin Diagn Res (2015) 0.75
Antibiotic-associated suspected adverse drug reactions among hospitalized patients in Uganda: a prospective cohort study. Pharmacol Res Perspect (2017) 0.75
HIV-related TB and adverse drug events. Thorax (2007) 0.75
Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals. Med J Armed Forces India (2017) 0.75
The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013). Medicine (Baltimore) (2017) 0.75
Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study. Clin Drug Investig (2017) 0.75
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med (2003) 7.40
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS (2002) 5.67
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax (1998) 4.52
Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis (1987) 4.11
Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis (2004) 3.40
Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet (1991) 3.19
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis (2006) 2.09
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med (1998) 1.85
Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis (1996) 1.70
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax (1996) 1.46
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 1.27
BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med (2005) 1.26
Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis (1996) 1.20
Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS (2000) 1.08
Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol (1993) 1.03
Use of Standard Therapy for Tuberculosis is Associated with Increased Adverse Reactions in Patients with HIV. Braz J Infect Dis (1997) 0.87
Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci (1973) 6.62
Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. BMJ (1997) 5.98
Human leukocyte interferon produced by E. coli is biologically active. Nature (1980) 5.86
Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet (2000) 5.66
Detection of Pneumocystis carinii with DNA amplification. Lancet (1990) 5.50
A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet (2001) 5.34
The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem (2005) 4.94
2-amino-4-phosphonobutyric acid: a new pharmacological tool for retina research. Science (1981) 4.63
Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology (1998) 4.01
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature (1990) 3.84
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax (2004) 3.77
Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax (2001) 3.72
The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ (1989) 3.43
Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: implications for developing management guidelines. Respir Med (1997) 3.38
Growth, survival, and resistance of the Legionnaires' disease bacterium. Ann Intern Med (1979) 3.36
Development and validation of a self-completed HIV symptom index. J Clin Epidemiol (2001) 3.28
S-nitrosothiols signal the ventilatory response to hypoxia. Nature (2001) 3.26
Open access clinic providing HIV-I antibody results on day of testing: the first twelve months. BMJ (1991) 3.17
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS (1997) 2.82
Novel antibiotic resistance transfer in Bacteroides. Antimicrob Agents Chemother (1982) 2.70
Prion protein is necessary for normal synaptic function. Nature (1994) 2.69
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Transferable tetracycline resistance in Clostridium difficile. Antimicrob Agents Chemother (1981) 2.56
Acute meningoencephalitis and meningitis due to primary HIV infection. BMJ (2002) 2.52
Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet (2001) 2.51
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Intracellular responses of the Müller (glial) cells of mudpuppy retina: their relation to b-wave of the electroretinogram. J Neurophysiol (1970) 2.45
Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin. Mol Biochem Parasitol (1990) 2.42
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
Insulin activates a tyrosine-specific protein kinase in extracts of 3T3-L1 adipocytes and human placenta. Proc Natl Acad Sci U S A (1982) 2.40
Theophylline prescribing, serum concentrations, and toxicity. Lancet (1983) 2.40
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol (1997) 2.35
Genetic and biochemical analysis of a novel Ambler class A beta-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob Agents Chemother (1993) 2.35
Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med (1996) 2.29
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet (1991) 2.21
The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol (2000) 2.20
Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol (1993) 2.17
Analysis of cepA and other Bacteroides fragilis genes reveals a unique promoter structure. FEMS Microbiol Lett (2000) 2.12
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis (2006) 2.09
Characterization of Bacteroides ovatus plasmid pBI136 and structure of its clindamycin resistance region. J Bacteriol (1985) 2.09
Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol (1998) 2.08
Large transmissible clindamycin resistance plasmid in Bacteroides ovatus. J Bacteriol (1984) 2.06
Development and use of cloning systems for Bacteroides fragilis: cloning of a plasmid-encoded clindamycin resistance determinant. J Bacteriol (1985) 2.06
Clinical cases in AIDS. 1. Br J Hosp Med (1992) 2.05
Epidemiology of cerebral palsy in England and Scotland, 1984-9. Arch Dis Child Fetal Neonatal Ed (1998) 2.01
Association between a GABRB3 polymorphism and autism. Mol Psychiatry (2002) 2.00
Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler class A beta-lactamases. Antimicrob Agents Chemother (1993) 1.94
Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS (1994) 1.93
Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. Histochem J (1990) 1.89
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Infect (1998) 1.84
Two independent conjugal transfer systems operating in Bacteroides fragilis V479-1. J Bacteriol (1982) 1.84
Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry (1994) 1.84
Tenofovir-associated renal and bone toxicity. HIV Med (2009) 1.82
Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J (2001) 1.81
Comparison of the transposon-like structures encoding clindamycin resistance in Bacteroides R-plasmids. Plasmid (1985) 1.80
Hybridization studies reveal homologies between pBF4 and pBFTM10, Two clindamycin-erythromycin resistance transfer plasmids of Bacteroides fragilis. J Bacteriol (1982) 1.79
How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis? Int J Tuberc Lung Dis (2008) 1.79
Extrachromosomal systems and gene transmission in anaerobic bacteria. Plasmid (1987) 1.78
HHV-6 in AIDS. Lancet (1994) 1.76
Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS (2009) 1.76
Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell (1996) 1.76
Escherichia coli delta 1-pyrroline-5-carboxylate reductase: gene sequence, protein overproduction and purification. Nucleic Acids Res (1982) 1.75
Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. Circ Res (1999) 1.73
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
AIDS and the lung: update 1992. 2. Recent developments in the management of the pulmonary complications of HIV disease. Thorax (1992) 1.72
Diagnosis of pulmonary disease in human immunodeficiency virus infection: role of transbronchial biopsy and bronchoalveolar lavage. Thorax (1989) 1.72
Infrared signature of structures associated with the H+(H2O)n (n = 6 to 27) clusters. Science (2004) 1.71
Studies of the optic nerve of the rhesus monkey: nerve fiber spectrum and physiological properties. Vision Res (1966) 1.70
Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet (1999) 1.69
Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J Infect Dis (1996) 1.68
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS (1997) 1.68
Nucleotide sequence analysis of tetracycline resistance gene tetO from Streptococcus mutans DL5. J Bacteriol (1988) 1.68
Biochemistry of Oleoresinosis : Monoterpene and Diterpene Biosynthesis in Lodgepole Pine Saplings Infected with Ceratocystis clavigera or Treated with Carbohydrate Elicitors. Plant Physiol (1987) 1.68
A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. Am J Hum Genet (1997) 1.68
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis (1998) 1.67
HIV infection and lymphoma. J Clin Pathol (2007) 1.67
Further observations on the pathological responses of rat skeletal muscle to toxins isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus. Clin Exp Pharmacol Physiol (1979) 1.66
Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell (1998) 1.66
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (1996) 1.64
Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin (2003) 1.62
Branhamella (Neisseria) catarrhalis--a lower respiratory tract pathogen? J Clin Microbiol (1981) 1.61